. Crawford J Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 7. Ohno R Tomonaga M Kobayashi T
Search Results
Yong Li, Xian Chen, Yanchun Qu, Jia-Ming Fan, Yan Li, Hui Peng, Yaojie Zheng, Yihong Zhang, and Hai-Bo Zhang
Symptoms of disease are often restricted to the involved organ, and 15% to 30% of patients present with fever, malaise, microcytic anemia, weight loss, thrombocytosis, elevated erythrocyte sedimentation rate, or polyclonal hypergammaglobulinemia. 3 Surgery
Presented by: Jimmy J. Caudell, David G. Pfister, and Randal S. Weber
febrile neutropenia. He received empiric antibiotics and antifungal medications, the neutropenia and fever resolved, and he was discharged. He did not require a nasal gastric tube or a PEG tube during treatment, and he went on to receive adjuvant
Richard I. Fisher
/chemotherapy arm experienced more neutropenia and fever; however, overall, treatment discontinuations were similar in both arms: 69% of patients on the R 2 arm and 71% of those on the rituximab/chemotherapy arm completed treatment. 13 Final data showed that R 2
Presented by: Natalie S. Callander
(84%), its severity was limited in most participants. “Patients typically develop a fever, chills, or changes in blood pressure within 24 hours of receiving idecabtagene vicleucel, but most are responsive to tocilizumab or steroids,” said Dr. Callander
Presented by: Kristin Dickinson, Halle C.F. Moore, Jennifer Schmitz, and Eric S. Zhou
Moderated by: Andrew T. Day
Center, University of Nebraska Medical Center, was 38 years old and a full-time nurse practitioner, wife, and active mother of 2 when she began experiencing recurrent infections. The infections led to constant fevers, bone pain, and mouth sores, and
Presented by: Deborah M. Stephens
leading to treatment discontinuation with zanubrutinib. One notable side effect of zanubrutinib was a tendency to cause more neutropenia, although this did not correlate to neutropenic fever or higher rates of grade 3 infections. “The findings of these 2
Presented by: Arlene O. Siefker-Radtke
personally am using growth factor support in all of my patients in [the setting of] sacituzumab govitecan because of neutropenia and neutropenic fever.” Combining Targeted Therapy With Immunotherapy “We are seeing a lot of excitement for [targeted
Presented by: Maria Alma Rodriguez
, and rubella (MMR), oral typhoid, yellow fever, rotavirus, nasal influenza, and varicella—are contraindicated or should be used with caution in actively immunocompromised cancer survivors and their close contacts. Per the NCCN Guidelines, live
Presented by: Aaron T. Gerds
70% of patients have symptoms driven primarily by cytokines, such as fevers and night sweats. Many patients also experience cytopenias, particularly anemia and thrombocytopenia. 2 , 3 “And, of course, it is a disease that carries a shortened life